Welcome to our dedicated page for Cogent Biosciences SEC filings (Ticker: COGT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cogent Biosciences filings document a biotechnology issuer focused on precision therapies for genetically defined diseases. Form 8-K reports record quarterly and annual financial results, bezuclastinib business updates, clinical-data presentations for GIST and Systemic Mastocytosis programs, and Regulation FD disclosures tied to trial results.
The filing record also covers capital-structure and governance matters, including common stock listed on the Nasdaq Global Select Market, a completed offering of 1.625% Convertible Senior Notes due 2031, material agreements such as corporate lease arrangements, and proxy statement items for director elections, auditor ratification and annual meeting voting matters.
Cogent Biosciences, Inc. reported that director Peter Evan Harwin was granted a stock option covering 17,901 shares of common stock at an exercise price of $31.98 per share. The option expires on June 9, 2036.
The option vests in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders, subject to his continued service. According to the disclosed arrangement, the option is held for investment vehicles managed by Fairmount Funds Management LLC, and Harwin is required to turn over any net cash or stock to the adviser, so he disclaims beneficial ownership.
Cogent Biosciences, Inc. director Karen Jean Ferrante received a new stock option grant covering 17,901 shares of common stock. The option has an exercise price of $31.98 per share and expires on June 9, 2036.
According to the award terms, the option will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided she continues serving the company through that date. Following this grant, she holds 17,901 stock options directly.
Cogent Biosciences, Inc. director Christopher W. Cain is associated with a grant of stock options covering 17,901 shares of common stock at an exercise price of $31.98 per share. The option expires on June 9, 2036 and vests in full upon the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders, subject to continued service.
Under an arrangement with Fairmount Funds Management LLC, Cain holds this option for one or more Fairmount investment funds and must turn over any net cash or stock received for the benefit of those funds. He therefore disclaims beneficial ownership of the option and the underlying common stock.
Cogent Biosciences director Todd Shegog received a new stock option award covering 17,901 shares of common stock. The options have an exercise price of $31.98 per share and expire on June 9, 2036. This grant increases his direct derivative holdings to 17,901 option shares.
The option will vest in full on the earlier of the first anniversary of the grant date or the date of the company’s 2027 Annual Meeting of Stockholders, provided Shegog continues to serve the company through that date. Until vesting and exercise, the award represents potential, not current, share ownership.
Cogent Biosciences director Arlene Morris received a stock option grant for 17,901 shares of common stock. The options have an exercise price of $31.98 per share and expire on June 9, 2036, representing compensation rather than an open-market trade.
The option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the date of the 2027 Annual Meeting of Stockholders, provided she continues serving the company through that date. After this grant, she directly holds stock options covering 17,901 underlying shares.
Cogent Biosciences director Matthew Ros received a stock option grant, not an open‑market trade. He was awarded options for 17,901 shares of common stock at an exercise price of $31.98 per share, expiring on June 9, 2036. The option vests in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders, conditioned on his continued service to the company through that date.
Cogent Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on June 9, 2026. As of the April 13, 2026 record date, 170,801,004 shares of common stock were entitled to vote.
All three director nominees, Chris Cain, Ph.D., Arlene Morris, and Todd Shegog, were elected. Stockholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm and approved the advisory vote on executive compensation.
Cogent Biosciences President and CEO Andrew Robbins reported two bona fide gifts of common stock. On May 19, 2026, he transferred 160,000 shares to a family trust for estate planning purposes and made a separate 160,000-share gift from his direct holdings.
After these transfers, Robbins’ direct ownership stands at 497,503 common shares, and the family trust holds 160,000 shares as an indirect position. These transactions were recorded at a price of $0.00 per share, reflecting that they were gifts rather than market sales.
Cogent Biosciences, Inc. Schedule 13G/A reports that Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and James E. Flynn each beneficially own 9,043,903 shares of common stock, representing 5.29% of the class as of 03/31/2026. The filing states these holdings are comprised of shares held by Deerfield Partners, L.P., with shared voting and dispositive power reported.
Cogent Biosciences reported a wider quarterly loss as it advances late‑stage drug programs and prepares for commercialization. Net loss for the three months ended March 31, 2026 was $97.4 million, up from $72.0 million a year earlier, driven by higher research and development expense of $75.4 million and general and administrative expense of $28.2 million as the company builds its commercial organization.
Cogent ended the quarter with $866.4 million in cash, cash equivalents and marketable securities and expects this to fund operations into 2028, including potential U.S. launches of bezuclastinib for systemic mastocytosis and GIST, pending approval. The company has submitted an NDA for bezuclastinib in Non‑Advanced Systemic Mastocytosis, accepted with a PDUFA date of December 30, 2026, and an NDA for bezuclastinib plus sunitinib in second‑line GIST under the Real‑Time Oncology Review program. A Phase 3 GIST trial showed median progression‑free survival of 16.5 months for the combination versus 9.2 months for sunitinib alone. Cogent also issued $230 million of 1.625% Convertible Senior Notes due 2031 and raised $45.7 million via its at‑the‑market equity program.